Hemodialysis patients obtain a robust humoral response from a third dose of the BNT162b2 vaccine, study finds

By | May 30, 2022
Researchers assessed the humoral immune responses generated by the third Pfizer-BioNTech BNT162b2 mRNA vaccination against SARS-CoV-2 among hemodialysis patients.